vTv Therapeutics (VTVT)

• Market cap: $133M
• 1 day: -7.18%
• 5 days: 16.87%
• 1 month: -9.24%
• 3 months: 8.31%
• 6 months: 141.41%
• Year to date: -14.47%
• 1 year: 59.76%
• 5 years: -68.17%
• 10 years: -86.52%
• Sector: Healthcare
• Industry: Biotechnology

About: vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

Employees: 23